Kaneka Nutrients announces The International Coenzyme Q10 Association Ninth Scientific Meeting

Press Release

The International Coenzyme Q₁₀ Association (ICQA; http://icqaproject.org/) is a non-profit organization that fosters basic and applied biomedical research on Coenzyme Q₁₀ (CoQ₁₀). Their mission is to advance knowledge on basic biochemistry and molecular genetics, as well as preventive and therapeutic effects of CoQ₁₀.  Kaneka Nutrients (www.kanekanutrients.com) is a founding member and proud to partner with ICQA for the Ninth Scientific Meeting to be held in at Columbia University in New York City June 21 – 24, 2018. 

"We have not held our Scientific Meeting in the United States in over 10 years. As such, we are excited to bring this meeting back to the United States.  Previous Scientific Meetings have been held in Japan and Europe," said Dr. Plácido Navas, Chairman of The International Coenzyme Q10 Association.

Every two to three years, nearly 350+ researchers and other professionals choose to attend the ICQA International Scientific Meeting to learn about the latest advances of Conventional CoQ₁₀ and the Ubiquinol form of CoQ10, meet with colleagues from around the world and strike new collaborations.

The critical goals of the IQCA are to promote international collaborative research efforts to expand scientific knowledge and to optimize the use of CoQ₁₀ as preventative and therapeutic interventions in human health. To achieve these important goals, ICQA organizes an international scientific meeting to present cutting-edge CoQ₁₀ and Ubiquinol CoQ₁₀ research in major clinical topics including: mitochondrial and degenerative diseases, aging, cardiovascular disorders, and nutritional supplementation needs and mechanisms that can benefit people suffering these conditions.

Dr. Navas added, "As in the 2015 Bologna Scientific Meeting, exciting sessions on the areas of CoQ₁₀ and Ubiquinol CoQ₁₀ research that have advanced significantly in the last few years will be presented including: mitochondrial diseases (primarily CoQ₁₀ deficiency syndrome), cardiovascular diseases, diabetes, and aging. There is evidence of efficacy of CoQ₁₀ supplementation in these conditions. Significantly, the European Medicines Agency has recently registered Ubiquinol as an orphan drug for CoQ₁₀ deficiency syndrome."

Mark your calendars for this important Scientific Meeting to learn about the advances of Conventional CoQ₁₀ and the Ubiquinol form of CoQ₁₀